Wegovy 10mg: what it is, what it isn't, and where you actually stand

You've found a listing for "Wegovy 10mg" (here's what's actually going on

Picture this: you've been reading about Wegovy, and somewhere) a forum, a social media post, maybe a website with prices listed, you spotted the phrase "semaglutide 10mg" or "Wegovy 10mg". It looks like a higher, more powerful option. It's not. The approved Wegovy injection in the UK does not come in a 10mg strength, at any stage of the titration schedule.

What you're almost certainly looking at is one of two things. First, a compounded semaglutide peptide preparation, typically sold as a powder for reconstitution, sometimes described by concentration (10mg per vial) rather than a per-dose figure. These are not the same as Wegovy. They are unlicensed, not manufactured to the same quality standards, and the MHRA has been explicit about the risks of obtaining weight-loss medicines from unverified sources. Second, it may simply be a mislabelled or fictitious product. If a site offers a "Wegovy 10mg" pen for sale without a prescription, that is a red flag, not a bargain.

The distinction between licensed semaglutide and unlicensed peptide preparations is worth understanding in full if you've come across these listings. In short: licensed Wegovy pens are manufactured and quality-controlled by Novo Nordisk; unlicensed semaglutide peptides are not, and their safety profile in practice is unknown.

For anything relating to weight management in the UK, the relevant medicine is Wegovy at its authorised doses, obtained through a valid prescription following clinical assessment. If you do encounter a vial-based preparation, our guide on how to mix 10mg semaglutide explains the reconstitution process and the practical risks involved, which is useful context for understanding why licensed pens are the safer route. That's the legal and safe route.

What the licensed Wegovy schedule actually looks like, and the new 7.2mg ceiling

For most people, Wegovy treatment begins at 0.25mg once weekly. That first dose isn't intended to produce significant weight loss on its own; it's there to let your body adjust to the medicine before stepping up. From there, the prescriber guides the titration through 0.5mg, 1.0mg, 1.7mg, and 2.4mg, with roughly four weeks at each level. The full Wegovy dose schedule explains each stage, including what to expect during the adjustment period.

Until early 2026, 2.4mg was the ceiling. Then, on 14 April 2026, the MHRA approved a dedicated single-dose 7.2mg pen, a higher maintenance option for adults with a BMI of 30 or above, titrated up through the existing schedule. Trials reported an average weight reduction of around 20.7% over 72 weeks at 7.2mg, which narrows the gap considerably with tirzepatide at its highest doses. This is a meaningful clinical development, covered in detail on the Wegovy treatment overview page.

The question of whether a higher dose works better is real and worth asking. According to NHS guidance on whether higher Wegovy doses produce greater results, the evidence generally supports more weight loss at higher doses, but tolerability is just as important as the dose number. Many people do very well at 1.7mg or 2.4mg. The prescriber's role is finding the highest dose your system handles comfortably, not automatically pushing to the maximum.

Side effects and why the titration schedule exists

Semaglutide's most common side effects are gastrointestinal, nausea, loose stools, constipation, reflux and belching appear in a meaningful proportion of users, particularly after starting or stepping up. The titration schedule is designed precisely to reduce this: slower increases give the gut time to adapt. Moving through doses faster than the prescriber recommends doesn't produce faster weight loss; it tends to produce more side effects.

For most people these effects are mild to moderate and ease within the first couple of weeks at a new dose. Severe, persistent stomach pain (particularly if it radiates toward the back) should always prompt urgent medical attention, as it can indicate a problem with the pancreas. The NHS patient information for semaglutide covers the full side-effect profile and is worth reading alongside your prescription.

Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. People with a history of medullary thyroid cancer or multiple endocrine neoplasia should discuss this with a prescriber before starting. Any side effect that concerns you should go back to the clinical team who prescribed it, not be managed alone.

If you want to report a suspected side effect, or to flag a concerning online seller, you can do so via the MHRA's Yellow Card scheme. That reporting genuinely helps the regulator monitor the real-world safety picture for newer medicines.

Getting Wegovy through a regulated UK pharmacy

Wegovy is a prescription-only medicine. The only legal route is a valid prescription, issued after clinical assessment by a registered prescriber who has reviewed your health history, current weight, and any relevant conditions. There is no shortcut to that process, and any site presenting one is not selling a legitimate medicine.

Through nume's free consultation, a GPhC-registered Independent Prescriber reads your answers the same day, a clinician, not automated software. If treatment is clinically appropriate, the prescription is written and the pharmacy dispatches it the same day for next-working-day delivery via DPD. The pen arrives in plain, unbranded packaging; there's no logo on the box, and you'll get a tracking link on your phone so you know exactly when it's coming.

To check that any online pharmacy is genuinely registered, look it up on the GPhC pharmacy register. It takes about thirty seconds and tells you everything you need to know about whether a pharmacy is operating legally. On the question of cost, the guide to where to buy Wegovy in the UK covers what to look for in a provider beyond the headline price.

For a broader look at weight-loss treatments available through a licensed UK pathway, the weight-loss treatments overview is a useful starting point if you're still weighing your options.